Clinical barriers to the use of recommended stroke prevention therapy

Stroke prevention therapy in atrial fibrillation is moderately tailored to recommended risk stratification. A minority of patients receiving a vitamin K antagonist have a proven effective time in therapeutic range for the international normalized ratio. Factors contributing to these evidence-practice gaps are 'clinical barriers'. Healthcare organization-level barriers include: lack of validated management tools, no structured patient education …